Jessica Stevens
Psychiatric/Mental Health · Keshena, WINPI 1194095588
Payments from drug & device makers
Across 126 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$300
- E.r. Squibb & Sons, L.L.C.$122
- Sunovion Pharmaceuticals Inc.$107
- Neurocrine Biosciences, Inc.$86
- Otsuka America Pharmaceutical, Inc.$57
- plus $173 from 7 others
What the payments were for
- Food & beverage$2,09495%
- Education$1115%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 82 | $1,358 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $300 |
| E.r. Squibb & Sons, L.L.C. | 5 | $122 |
| Sunovion Pharmaceuticals Inc. | 7 | $107 |
| Neurocrine Biosciences, Inc. | 6 | $86 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| AbbVie(2 entities) | 2 | $32 |
| Indivior Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$464
- LYBALVI$426
- CAPLYTA$116
- ARISTADA INITIO$116
How this compares
$2,204 in reported general payments places this provider in the 80th percentile of 384 psychiatric/mental health providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 51 | $411,631 |
| RexultiBrexpiprazole | 199 | $305,501 |
| Invega TrinzaPaliperidone Palmitate | 29 | $271,488 |
| Austedo XrDeutetrabenazine | 24 | $200,266 |
| Invega SustennaPaliperidone Palmitate | 62 | $164,258 |
| AristadaAripiprazole Lauroxil | 56 | $162,389 |
| VraylarCariprazine Hcl | 93 | $135,254 |
| TrintellixVortioxetine Hydrobromide | 142 | $74,507 |
| Abilify MaintenaAripiprazole | 25 | $55,054 |
| LybalviOlanzapine/Samidorphan Malate | 30 | $43,207 |
| VyvanseLisdexamfetamine Dimesylate | 118 | $42,595 |
| Aripiprazole | 153 | $16,393 |
| Lisdexamfetamine Dimesylate | 80 | $13,781 |
| Depakote ErDivalproex Sodium | 18 | $7,690 |
| ConcertaMethylphenidate Hcl | 18 | $6,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Concerta | $15 | $442,304109 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $86 | $411,63151 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $57 | $360,555224 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,358 | $205,59686 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $49 | $200,26624 claims |
| AbbVieVraylar | $32 | $135,25493 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $34 | $117,103260 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 384 psychiatric/mental health providers in Wisconsin.
Other psychiatric/mental health in Keshena
- Carolyn DavidsonMilwaukee$46K
- Sherry AleksichMilwaukee$33K
- Bobbi DurstPewaukee$23K
- Ngozi ObioraMilwaukee$19K
- Glenda McConnellGreen Bay$14K
- Debra BenishekGreen Bay$12K
- Shalonda MylesBrown Deer$12K
- Victoria McGinleyMilwaukee$9K
- Janet BurnsBrookfield$9K
- Alyssa SkalitzkyKenosha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.